FDA. Guidance For Industry. Investigator Responsibilities – Protecting The Rights, Safety, And Welfare Of Study Subjects.
I. INTRODUCTION
This guidance represents the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.
This guidance provides an overview of the responsibilities of a person who conducts a clinical investigation of a drug, biological product, or medical device (an investigator as defined in 21 CFR 312.3(b) and 21 CFR 812.3(i)). The goal of this guidance is to help investigators better meet their responsibilities with respect to protecting human subjects and ensuring the integrity of the data from clinical investigations. This guidance is intended to clarify for investigators and sponsors FDA’s expectations concerning the investigator’s responsibility (1) to supervise a clinical study in which some study tasks are delegated to employees or colleagues of the investigator or other third parties and (2) to protect the rights, safety, and welfare of study subjects.
FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.
Authors:
Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Center for Biologics Evaluation and Research
OCTOBER 2009
Clinical Research News
Предстоящие клинические испытания
-
Intuitive SurgicalЕще не набираютМитральная регургитация (MR)
-
Bristol-Myers SquibbЕще не набирают
-
University of Alabama at BirminghamЕще не набираютSpinal Cord DisordersСоединенные Штаты
-
Medical University of ViennaЕще не набираютСосудистый доступ | Осложнение сосудистого доступа | Инфекции диализного катетера | Гемодиализ | Осложнение гемодиализа | Нарушение доступа к диализу | ТХПН (конечная стадия почечной болезни) | Диализный катетерАвстрия
-
NYU Langone HealthNational Cancer Institute (NCI)Еще не набираютРак простатыСоединенные Штаты
-
M.D. Anderson Cancer CenterЕще не набираютКожная ангиосаркомаСоединенные Штаты
-
Helwan UniversityЕще не набираютХирургическая инфекция области хирургического вмешательства (ХИОХВ)
-
Prevention Strategies, LLCNational Institute on Drug Abuse (NIDA); NORC at the University of ChicagoЕще не набираютРасстройства, связанные с алкоголем | Расстройство, связанное с употреблением табака | Использование марихуаны | Нарушения, связанные с употреблением психоактивных веществ
-
Second Affiliated Hospital of Nanchang UniversityBeijing Pearl Biotechnology Limited Liability CompanyРекрутингНемелкоклеточный рак легкогоКитай
-
Ming LiuЕще не набираютАденокарцинома желудка | Аденокарцинома желудочно-пищеводного соединенияКитай
-
The First Affiliated Hospital of Soochow UniversityЕще не набираютПодслизистые опухоли желудка
-
Peking University First HospitalPeking University Shenzhen HospitalЕще не набираютПожилые пациенты | Хирургия рака | Целевое управление температурой | Гипотермия, Случайный | Отсроченное нейрокогнитивное восстановлениеКитай
Clinical Research Jobs
-
United Kingdom - London
-
Germany - Hessen
-
United States - North Carolina - Durham
-
Poland - Krakow
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China
